Liver X and farnesoid X

Overview: Liver X and farnesoid X receptors (LXR and FXR, provisional nomenclature) are members of a steroid analogue-activated nuclear receptor subfamily (ENSF00000000720), which form heterodimers with members of the retinoid X receptor family. Endogenous ligands for LXRs include hydroxycholesterols (OHC), while FXR appears to be activated by bile acids.

Nomenclature	**LXRα**	**LXRβ**	**FXR**
Other names	NR1H3, oxysterols receptor α	NR1H2, oxysterols receptor β, ubiquitously expressed nuclear receptor	NR1H4, bile acid receptor
Ensembl ID	ENSG00000025434	ENSG00000131408	ENSG00000012504
Potency order	20S-OHC, 22R-OHC, 24S-OHC > 25-OHC, 27-OHC (Lehmann *et al*., 1997)	20S-OHC, 22R-OHC, 24S-OHC > 25-OHC, 27-OHC (Lehmann *et al*., 1997)	Chenodeoxycholate > lithocholate, deoxycholate (Makishima *et al*., 1999; Parks *et al*., 1999)
Selective agonists	—	—	ECDCA (Pellicciari *et al*., 2002)
Selective antagonists	—	—	Guggulsterone (Urizar *et al*., 2002)

TO901317 (Repa *et al*., 2000) and GW3965 (Collins *et al*., 2002) are synthetic agonists acting at both LXRα and LXRβ with less than 10-fold selectivity.

Abbreviations: **ECDCA**, 6α-ethyl-chenodeoxycholate, also known as INT747; **guggulsterone**, *trans*-4,17(20)-pregnadiene-3,16-dione; **GW3965**, 3-(3-[*N*-{2-chloro-3-trifluoromethylbenzyl}-{2,2-diphenylethyl}amino]propyloxy)phenylacetic acid hydrochloride; **OHC**, hydroxycholesterol; **TO901317**, *N*-(2,2,2-trifluoroethyl)-*N*-(4-[2,2,2-trifluoro-1-hydroxy-1-{trifluoromethyl}ethyl]phenyl)-benzenesulfonamide

Further Reading:

BARISH, G.D. & EVANS, R.M. (2004). PPARs and LXRs: atherosclerosis goes nuclear. *Trends Endocrinol. Metab.,* **15,** 158–165.

BOCHER, V., MILLATT, L.J., FRUCHART, J.C. & STAELS, B. (2003). Liver X receptors: new players in atherogenesis? *Curr. Opin. Lipidol.,* **14,** 137–143.

BRADLEY, M.N. & TONTONOZ, P. (2005). LXR: A nuclear receptor target for cardiovascular disease? *Drug Discov. Today: Ther. Strat.,* **2,** 97–103.

CLAUDEL, T., STURM, E., KUIPERS, F. & STAELS, B. (2004). The farnesoid X receptor: a novel drug target? *Expert Opin. Investig. Drugs,* **13,** 1135–1148.

GEYEREGGER, R., ZEYDA, M. & STULNIG, T.M. (2006). Liver X receptors in cardiovascular and metabolic disease. *Cell Mol. Life Sci.,* **63,** 524–539.

HANDSCHIN, C. & MEYER, U.A. (2005). Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. *Arch. Biochem. Biophys.,* **433,** 387–396.

HOUTEN, S.M., WATANABE, M. & AUWERX, J. (2006). Endocrine functions of bile acids. *EMBO J.,* **25,** 1419–1425.

KALAANY, N.Y. & MANGELSDORF, D.J. (2006). LXRS and FXR: the yin and yang of cholesterol and fat metabolism. *Annu. Rev. Physiol.,* **68,** 159–191.

LEE, C.H. & PLUTZKY, J. (2006). Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune? *Circulation,* **113,** 5–8.

MILLATT, L.J., BOCHER, V., FRUCHART, J.C. & STAELS, B. (2003). Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. *Biochim. Biophys. Acta,* **1631,** 107–118.

PELLICCIARI, R., COSTANTINO, G. & FIORUCCI, S. (2005). Farnesoid X receptor: from structure to potential clinical applications. *J. Med. Chem.,* **48,** 5383–5403.

REPA, J.J. & MANGELSDORF, D.J. (2002). The liver X receptor gene team: potential new players in atherosclerosis. *Nat. Med.,* **8,** 1243–1248.

TONTONOZ, P. & MANGELSDORF, D.J. (2003). Liver X receptor signaling pathways in cardiovascular disease. *Mol. Endocrinol.,* **17,** 985–993.

ULVEN, S.M., DALEN, K.T., GUSTAFSSON, J.A. & NEBB, H.I. (2005). LXR is crucial in lipid metabolism. *Prostaglandins Leukot. Essent. Fatty Acids,* **73,** 59–63.

ZELCER, N. & TONTONOZ, P. (2006). Liver X receptors as integrators of metabolic and inflammatory signaling. *J. Clin. Invest.,* **116,** 607–614.

References:

COLLINS, J.L. *et al*. (2002). *J. Med. Chem.,* **45,** 1963–1966.

LEHMANN, J.M. *et al*. (1997). *J. Biol. Chem.,* **272,** 3137–3140.

MAKISHIMA, M. *et al*. (1999). *Science,* **284,** 1362–1365.

PARKS, D.J. *et al*. (1999). *Science,* **284,** 1365–1368.

PELLICCIARI, R. *et al*. (2002). *J. Med. Chem.,* **45,** 3569–3572.

REPA, J.J. *et al*. (2000). *Science,* **289,** 1524–1529.

URIZAR, N.L. *et al*. (2002). *Science,* **296,** 1703–1706.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.,* **150** (Suppl. 1), S1–S168.

Peroxisome proliferator-activated

Overview: Peroxisome proliferator-activated receptors (PPARs, provisional nomenclature) are nuclear hormone receptors of the NR1C family, with diverse roles regulating lipid homeostasis, cellular differentiation, proliferation and the immune response. PPARs have many potential endogenous agonists (see Bishop-Bailey & Wray, 2003), including 15-deoxy-$\Delta^{12,14}$-prostaglandin J_2, prostacyclin, many fatty acids and their oxidation products, lysophosphatidic acid (McIntyre *et al*., 2003), 13-HODE, 15-HETE, Paz-PC, azelaoyl-PAF, and leukotriene B_4. These receptors also bind hypolipidemic drugs (PPARα) and antidiabetic thiazolidinediones (PPARγ). Once activated by a ligand, the receptor forms a heterodimer with members of the retinoid X receptor family and can act as a transcription factor. Although radioligand-binding assays have been described for all three receptors, the radioligands are not commercially available.

Nomenclature	**PPARα**	**PPARβ**	**PPARγ**
Other names	NR1C1	NR1C2, NUC1, FAAR, PPARδ	NR1C3
Ensemble ID	ENSG00000100406	ENSG00000112033	ENSG00000132170
Selective agonists	GW7647, WY14643, clofibrate, fenofibrate, bezafibrate, ciprofibrate, gemfibrozil	L165041, GW501516, GW0742	Rosiglitazone (BRL49653), ciglitazone, troglitazone, pioglitazone, CDDO, GW1929
Selective antagonists	MK886 (Kehrer *et al*., 2001), GW6471 (Xu et al., 2002)	Sulindac (He *et al*., 1999)	CDDO-Me ([Wang *et al*., 2000), GW9662 (Huang *et al*., 1999), diclofenac (6.2, Adamson *et al*., 2002), BADGE (4.0, Wright *et al*., 2000), T0070907 (Lee *et al*., 2002)

As with the estrogen receptor antagonists, many agents show tissue-selective efficacy (e.g. Bishop-Bailey *et al*., 2000; Nakamuta *et al*., 2002; Rocchi *et al*., 2001). Agonists with mixed activity at PPARα and PPARγ have recently been described (e.g. Doebber *et al*., 2004; Guo *et al*., 2004; Xu *et al*., 2004).

Abbreviations: **13-HODE**, 13-hydroxyoctadecadienoic acid; **15-HETE**, 15-hydroxyeicosatetraenoic acid; **Azelaoyl-PAF**, 1-*O*-hexadecyl-2-*O*-(9-carboxyoctanoyl)-sn-glyceryl-3-phosphocholine; **BADGE**, bisphenol A diglycidyl ether; **CDDO**, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid; **CDDO-Me**, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester; **GW1929**, (2*S*)-([2-benzoylphenyl]amino)-3-(4-[2-{methylpyridin-2-ylamino}ethoxy]phenyl)propionic acid; **GW501516**, 2-methyl-4(((4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)methyl)sulfanyl)phenoxy)acetic acid; **GW7647**, 2-([4-{2-([{cyclohexylamino}carbonyl][4-cyclohexylbutyl]amino)ethyl}phenyl]thio)-2-methylpropanoic acid; **GW9662**, 2-chloro-5-nitro-*N*-phenylbenzamide; **L165041**, (4-[3-{4-acetyl-3-hydroxy-2-propylphenoxy}propoxyl]phenoxy)acetic acid; **MK886**, 3-(1-[*p*-chlorobenzyl]-5-[isopropyl]-3-tert-butylthioindol-2-yl)-2,2-dimethylpropanoic acid methyl ester; **Paz-PC**, 1-palmitoyl-2-azelaoyl-*sn*-glycero-3-phosphocholine; **T0070907**, 2-chloro-5-nitro-*N*-(4-pyridyl)benzamide; **WY14643**, 2-(4-chloro-6-[{2,3-dimethylphenyl}amino]pyrimidin-2-yl)sulphanylacetic acid, also known as pirinixic acid

Further Reading:

AUWERX, J. (2002). Nuclear receptors. I. PPARγ in the gastrointestinal tract: gain or pain? *Am. J. Physiol. -Gastrointest. Liver Physiol.,* **282,** G581–G585.

BERGER, J. & MOLLER, D.E. (2002). The mechanisms of action of PPARs. *Annu. Rev. Med.,* **53,** 409–435.

BERGER, J.P., AKIYAMA, T.E. & MEINKE, P.T. (2005). PPARs: therapeutic targets for metabolic disease. *Trends Pharmacol. Sci.,* **26,** 244–251.

BERKENSTAM, A. & GUSTAFSSON, J.A. (2005). Nuclear receptors and their relevance to diseases related to lipid metabolism. *Curr. Opin. Pharmacol.,* **5,** 171–176.

BISHOP-BAILEY, D. & WRAY, J. (2003). Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. *Prostaglandins Other Lipid Mediat.,* **71,** 1–22.

CHINETTI-GBAGUIDI, G., FRUCHART, J.C. & STAELS, B. (2005). Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. *Curr. Opin. Pharmacol.,* **5,** 177–183.

DAYNES, R.A. & JONES, D.C. (2002). Emerging roles of PPARs in inflammation and immunity. *Nat. Rev. Immunol.,* **2,** 748–759.

DESVERGNE, B., MICHALIK, L. & WAHLI, W. (2004). Be fit or be sick: peroxisome proliferator-activated receptors are down the road. *Mol. Endocrinol.,* **18,** 1321–1332.

DUVAL, C., CHINETTI, G., TROTTEIN, F., FRUCHART, J.C. & STAELS, B. (2002). The role of PPARs in atherosclerosis. *Trends Mol. Med.,* **8,** 422–430.

FEINSTEIN, D.L., SPAGNOLO, A., AKAR, C., WEINBERG, G., MURPHY, P., GAVRILYUK, V. & RUSSO, C.D. (2005). Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? *Biochem. Pharmacol.,* **70,** 177–188.

FRANCIS, G.A., ANNICOTTE, J.S. & AUWERX, J. (2003). PPAR agonists in the treatment of atherosclerosis. *Curr. Opin. Pharmacol.,* **3,** 186–191.

FRANCIS, G.A., FAYARD, E., PICARD, F. & AUWERX, J. (2003). Nuclear receptors and the control of metabolism. *Annu. Rev. Physiol.,* **65,** 261–311.

LAZAR, M.A. (2001). Progress in cardiovascular biology: PPAR for the course. *Nat. Med.,* **7,** 23–24.

LEHRKE, M. & LAZAR, M.A. (2005). The many faces of PPARγ. *Cell,* **123,** 993–999.

LI, A.C. & PALINSKI, W. (2006). Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. *Annu. Rev. Pharmacol. Toxicol.,* **46,** 1–39.

MANDARD, S., MULLER, M. & KERSTEN, S. (2004). Peroxisome proliferator-activated receptor alpha target genes. *Cell. Mol. Life Sci.,* **61,** 393–416.

NICHOLSON, A.C. (2004). Expression of CD36 in macrophages and atherosclerosis the role of lipid regulation of PPAR-γ signaling. *Trends Cardiovasc. Med.,* **14,** 8–12.

PEGORIER, J.P., MAY, C.L. & GIRARD, J. (2004). Control of gene expression by fatty acids. *J. Nutr.,* **134,** 2444S–2449S.

PICARD, F. & AUWERX, J. (2002). PPARγ and glucose homeostasis. *Annu. Rev. Nutr.,* **22,** 167–197.

SAMPATH, H. & NTAMBI, J.M. (2005). Polyunsaturated fatty acid regulation of genes of lipid metabolism. *Annu. Rev. Nutr.,* **25,** 317–340.

SCHIFFRIN, E.L. (2005). Peroxisome proliferator-activated receptors and cardiovascular remodeling. *Am. J. Physiol. -Heart Circ. Physiol.,* **288,** H1037–H1043.

STAELS, B. & FRUCHART, J.C. (2005). Therapeutic roles of peroxisome proliferator-activated receptor agonists. *Diabetes,* **54,** 2460–2470.

TAN, N.S., MICHALIK, L., DESVERGNE, B. & WAHLI, W. (2005). Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. *J. Steroid Biochem. Mol. Biol.,* **93,** 99–105.

WOLF, G. (2004). Tissue-specific knockout defines peroxisome proliferator-activated receptor γ function in muscle and liver. *Nutr. Rev.,* **62,** 253–255.

References:

ADAMSON, D.J. *et al*. (2002). *Mol. Pharmacol.,* **61,** 7–12.

BISHOP-BAILEY, D. *et al*. (2000). *Br. J. Pharmacol.,* **131,** 651–654.

DOEBBER, T.W. *et al*. (2004). *Biochem. Biophys. Res. Commun.,* **318,** 323–328.

GUO, Q. *et al*. (2004). *Endocrinology,* **145,** 1640–1648.

HE, T.C. *et al*. (1999). *Cell,* **99,** 335–345.

KEHRER, J.P. *et al*. (2001). *Biochem J,* **356,** 899–906.

LEE, G. *et al*. (2002). *J. Biol. Chem.,* **277,** 19649–19657.

MCINTYRE, T.M. *et al*. (2003). *Proc. Natl. Acad. Sci. U.S.A.,* **100,** 131–136.

NAKAMUTA, M. *et al*. (2002). *Cell. Biol. Int.,* **26,** 235–241.

ROCCHI, S. *et al*. (2001). *Mol. Cell.,* **8,** 737–747.

WANG, Y. *et al*. (2000). *Mol. Endocrinol.,* **14,** 1550–1556.

WRIGHT, H.M. *et al*. (2000). *J. Biol. Chem.,* **275,** 1873–1877.

XU, H.E. *et al*. (2002). *Nature,* **415,** 813–817.

XU, Y. *et al*. (2004). *J. Med. Chem.,* **47,** 2422–2425.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.,* **150** (Suppl. 1), S1–S168.

Retinoic acid and retinoid X

Overview: Retinoic acid receptors (provisional nomenclature) are nuclear hormone receptors of the NR1B family, with the vitamin A-derived agonists all-*trans* retinoic acid (ATRA) and 9-*cis*-retinoic acid, and the RAR-selective synthetic agonist TTNPB. Retinoid X receptors are NR2B family members and are activated by 9-*cis*-retinoic acid and the RXR-selective agonists LGD1069 and LG100268. These receptors form RXR–RAR heterodimers and RXR–RXR homodimers (Mangelsdorf and Evans, 1995; Chambon, 1996). Cytoplasmic cellular retinoid binding proteins I (ENSG00000114115), II (ENSG00000114113), III (ENSG00000139194) and IV (ENSG00000162444) are thought to control the levels of intracellular retinoids available for interaction with their receptors (Li, 1999). [^{3}H]-ATRA and [^{3}H]-9-*cis*-retinoic acid have been used to label RARs and RXRs, respectively.

Nomenclature	**RARα**	**RARβ**	**RARγ**
Other names	NR1B1	NR1B2, HBV-activated protein	NR1B3
Ensembl ID	ENSG00000131759	ENSG00000077092	ENSG00000172819
Selective agonists	Ro406055 (Delescluse *et al*., 1991)	—	—
Selective antagonists	Ro415253 (Apfel *et al*., 1992)	—	—

LE135 is an antagonist with selectivity for RARα and RARβ compared to RARγ (Li *et al*., 1999)

Nomenclature	**RXRα**	**RXRβ**	**RXRγ**
Other names	NR2B1	NR2B2	NR2B3
Ensembl ID	ENSG00000078380	ENSG00000112472	ENSG00000143171

ATRA has been suggested to be a ligand for the orphan nuclear receptor RORβ (Stehlin-Gaon *et al*., 2003).

Abbreviations: **ATRA**, all-*trans*-retinoic acid; **LE135**, 4-(7,8,9,10-tetrahydro-5,7,7,10,10-pentamethyl-5*H*-benzo[*e*]naphtho[2,3-*b*][1,4]diazepin-13-yl)benzoic acid; **LG100268**, 6-(1-[3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopropyl) nicotinic acid; **LGD1069**, 4-(1-[3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl]ethenyl) benzoic acid; **Ro406055**, 4-([5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carboxamido)benzoic acid (also known as AM580); **Ro415253**, 4-[2-(7-heptoxy-4,4-dimethyl-1,1-dioxo-2,3-dihydrothiochromen-6-yl)prop-1-enyl]benzoic acid, also known as LG629; **TTNPB**, (*E*)-4-(2-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]-1-propenyl)benzoic acid

Further Reading:

ABU, J., BATUWANGALA, M., HERBERT, K. & SYMONDS, P. (2005). Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer. *Lancet Oncol.,* **6,** 712–720.

COLLINS, S.J. (2002). The role of retinoids and retinoic acid receptors in normal hematopoiesis. *Leukemia,* **16,** 1896–1905.

DAWSON, M.I. & ZHANG, X.K. (2002). Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-*trans*-retinoic acid and 9-*cis*-retinoic acid. *Curr. Med. Chem.,* **9,** 623–637.

LEFEBVRE, P. (2001). Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities. *Curr. Drug Targets Immun. Endocr. Metabol. Disord.,* **1,** 153–164.

SHULMAN, A.I. & MANGELSDORF, D.J. (2005). Retinoid X receptor heterodimers in the metabolic syndrome. *N. Engl. J. Med.*, **353,** 604–615.

SOPRANO, D.R., QIN, P. & SOPRANO, K.J. (2004). Retinoic acid receptors and cancer. *Annu. Rev. Nutr.,* **24,** 201–221.

WEI, L.N. (2003). Retinoid receptors and their coregulators. *Annu. Rev. Pharmacol. Toxicol.,* **43,** 47–72.

YANG, Q., SAKURAI, T. & KAKUDO, K. (2002). Retinoid, retinoic acid receptor β and breast cancer. *Breast Cancer Res. Treat.,* **76,** 167–173.

References:

APFEL, C. *et al*. (1992). *Proc. Natl. Acad. Sci. U.S.A.,* **89,** 7129–7133.

CHAMBON, P. (1996). *FASEB J.,* **10,** 940–954.

DELESCLUSE, C. *et al*. (1991). *Mol. Pharmacol.,* **40,** 556–562.

LI, E. (1999). *Mol. Cell. Biochem.,* **192,** 105–108.

LI, Y. *et al*. (1999). *J. Biol. Chem.,* **274,** 15360–15366.

MANGELSDORF, D.J. & EVANS, R.M. (1995). *Cell,* **83,** 841–850.

STEHLIN-GAON, C. *et al*. (2003). Drft. *Nat. Struct. Biol.,* **10,** 820–825.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.,* **150** (Suppl. 1), S1–S168.

Steroid hormone

Overview: Steroid hormone receptors are nuclear hormone receptors of the NR3 class, with endogenous agonists that include 5α-dihydrotestosterone (DHT), aldosterone, cortisol, corticosterone, progesterone, testosterone and estradiol. These receptors exist as dimers coupled with chaperone molecules (such as HSP90 and immunophilin HSP65), which are shed on binding the steroid hormone. The activated receptors then bind to nuclear hormone response elements of the genome, with a 15-nucleotide consensus sequence AGAACAnnnTGTTCT (i.e. an inverted palindrome) as homo- or heterodimers. They also affect transcription by protein–protein interactions with other transcription factors, such as activator protein 1 (AP-1) and nuclear factor κB (NF-κB). Splice variants of each of these receptors can form functional or nonfunctional monomers that can dimerize to form functional or non-functional receptors. For example, alternative splicing of PR mRNA produces A and B monomers that combine to produce functional AA, AB and BB receptors with distinct characteristics (Vegeto *et al*., 1993).

7TM receptors responsive to estrogen and progestins have recently been described in man (Filardo and Thomas, 2005; Zhu *et al*., 2003a, b), although their physiological significance has yet to be elucidated.

Nomenclature	**Mineralocorticoid**	**Glucocorticoid**	**Progesterone**	**Androgen**
Preferred abbreviation	MR	GR	PR	AR
Other names	Type I glucocorticoid receptor, aldosterone receptor	Type II glucocorticoid receptor	—	dihydrotestosterone receptor
Ensembl ID	ENSG00000151623	ENSG00000113580	ENSG00000082175	ENSG00000169083
Rank order of potency	Corticosterone = cortisol = aldosterone = progesterone (Rupprecht *et al*., 1993)	Cortisol, corticosterone ≫aldosterone, deoxycortisone (Rupprecht *et al*., 1993)	Progesterone	DHT > testosterone
Selective agonists	Aldosterone	RU28362, RU26988	ORG2058, progesterone	DHT, mibolerone, R1881
Selective antagonists	RU28318, ZK112993, onapristone	Mifepristone, ZK112993, onapristone	Mifepristone, ZK112993, onapristone	Hydroxyflutamide
Probes	[^{3}H]-Aldosterone	[^{3}H]-Dexamethasone	[^{3}H]-ORG2058	[^{3}H]-DHT, [^{3}H]-mibolerone, [^{3}H]-R1881

[^{3}H]-Dexamethasone also binds to MR *in vitro*. PR antagonists have been suggested to subdivide into Type I (e.g. onapristone) and Type II (e.g. ZK112993) groups. These groups appear to promote binding of PR to DNA with different efficacies and evoke distinct conformational changes in the receptor, leading to a transcription-neutral complex (Gass *et al*., 1998; Leonhardt *et al*., 1998). Mutations in AR underlie testicular feminization and androgen insensibility syndromes, spinal and bulbar muscular atrophy (Kennedy's disease).

Nomenclature	**Estrogen α**	**Estrogen β**
Preferred abbreviation	ERα	ERβ
Other names	Estradiol	Estradiol
Ensembl ID	ENSG00000091831	ENSG00000140009

Estrogen receptors may be blocked nonselectively by tamoxifen and raloxifene, and labelled by [^{3}H]-estradiol and [^{3}H]-tamoxifen. Many agents thought initially to be antagonists at estrogen receptors appear to have tissue-specific efficacy (e.g. tamoxifen is an antagonist at estrogen receptors in the breast, but is an agonist at estrogen receptors in the uterus), hence the descriptor SERM (selective estrogen receptor modulator). Additional 'orphan' estrogen-receptor-related proteins have been described (ERRα ENSG00000173153; ERRβ ENSG00000119715; ERRγ ENSG00000057103).

Abbreviations: **ORG2058**, 16-α-ethyl-21-hydroxy-19-norpregn-4-ene-3,20-dione; **R1881**, 17β-hydroxy-17α-methyl-estra-4,9,11-triene-3-one, also known as methyltrienolone; **RU26988**, 11β,17β-dihydroxy-21-methyl-17α-pregna-1,4,6-trien-20-yl-3-on; **RU28318**, 3-oxo-7-propyl-17-hydroxy-androstan-4-en-17-yl; **RU28362**, 11β,17β-dihydroxy-6-methyl-17-(1-propionyl)androsta-1,4,6-triene-3-one; **ZK112993**, 11β-(4-acetylphenyl)-17β-hydroxyl-17α-(1-propinyl)-4,8-estradiene-3-one

Further Reading:

BERKENSTAM, A. & GUSTAFSSON, J.A. (2005). Nuclear receptors and their relevance to diseases related to lipid metabolism. *Curr. Opin. Pharmacol.,* **5,** 171–176.

BIAN, Z., NILSSON, S. & GUSTAFSSON, J.A. (2001). Selective estrogen receptor modulators and coronary heart disease. *Trends Cardiovasc. Med.,* **11,** 196–202.

CLARKE, R., LEONESSA, F., WELCH, J.N. & SKAAR, T.C. (2001). Cellular and molecular pharmacology of antiestrogen action and resistance. *Pharmacol. Rev.,* **53,** 25–71.

DUBEY, R.K., TOFOVIC, S.P. & JACKSON, E.K. (2004). Cardiovascular pharmacology of estradiol metabolites. *J. Pharmacol. Exp. Ther.,* **308,** 403–409.

EDWARDS, D.P. (2005). Regulation of signal transduction pathways by estrogen and progesterone. *Annu. Rev. Physiol.,* **67,** 335–376.

GELMANN, E.P. (2002). Molecular biology of the androgen receptor. *J. Clin. Oncol.,* **20,** 3001–3015.

GIGUERE, V. (2002). To ERR in the estrogen pathway. *Trends Endocrinol. Metab.,* **13,** 220–225.

GRAY, G.A., SHARIF, I., WEBB, D.J. & SECKL, J.R. (2001). Oestrogen and the cardiovascular system: the good, the bad and the puzzling. *Trends Pharmacol. Sci.,* **22,** 152–156.

HESS, R.A., BUNICK, D. & BAHR, J. (2001). Oestrogen, its receptors and function in the male reproductive tract – a review. *Mol. Cell. Endocrinol.,* **178,** 29–38.

HU, X. & FUNDER, J.W. (2006). The evolution of mineralocorticoid receptors. *Mol. Endocrinol.,* **20,** 1471–1478.

KOS, M., REID, G., DENGER, S. & GANNON, F. (2001). Minireview: genomic organization of the human ERα gene promoter region. *Mol. Endocrinol.,* **15,** 2057–2063.

LEWANDOWSKI, S., KALITA, K. & KACZMAREK, L. (2002). Estrogen receptor β. Potential functional significance of a variety of mRNA isoforms. *FEBS Lett.,* **524,** 1–5.

MARINELLI, M. & PIAZZA, P.V. (2002). Interaction between glucocorticoid hormones, stress and psychostimulant drugs. *Eur. J. Neurosci.,* **16,** 387–394.

PARK, W.C. & JORDAN, V.C. (2002). Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. *Trends Mol. Med.,* **8,** 82–88.PRESCOTT, J. & COETZEE, G.A. (2006).

PATTEN, R.D. & KARAS, R.H. (2006). Estrogen replacement and cardiomyocyte protection. *Trends Cardiovasc. Med.,* **16,** 69–75.

PETTERSSON, K. & GUSTAFSSON, J.A. (2001). Role of estrogen receptor β in estrogen action. *Annu. Rev. Physiol.,* **63,** 165–192.

PICARD, D. (2006). Chaperoning steroid hormone action. *Trends Endocrinol. Metab.,* **17,** 229–235.

PFAFF, D., FROHLICH, J. & MORGAN, M. (2002). Hormonal and genetic influences on arousal – sexual and otherwise. *Trends Neurosci.,* **25,** 45–50.

PRESCOTT, J. & COETZEE, G.A. (2006). Molecular chaperones throughout the life cycle of the androgen receptor. *Cancer Lett.,* **231,** 12–19.

SYED, F. & KHOSLA, S. (2005). Mechanisms of sex steroid effects on bone. *Biochem. Biophys. Res. Commun.,* **328,** 688–696.

YUDT, M.R. & CIDLOWSKI, J.A. (2002). The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. *Mol. Endocrinol.,* **16,** 1719–1726.

References:

FILARDO, E.J. & THOMAS, P. (2005). *Trends Endocrinol. Metab.,* **16,** 362–367.

GASS, E.K. *et al*. (1998). *Endocrinology,* **139,** 1905–1919.

LEONHARDT, S.A. *et al*. (1998). *Mol. Endocrinol.,* **12,** 1914–1930.

RUPPRECHT, R. *et al*. (1993). *Eur. J. Pharmacol.,* **247,** 145–154.

VEGETO, E. *et al*. (1993). *Mol. Endocrinol.,* **7,** 1244–1255.

ZHU, Y. *et al*. (2003a). *Proc. Natl. Acad. Sci. U.S.A.,* **100,** 2237–2242.

ZHU, Y. *et al*. (2003b). *Proc. Natl. Acad. Sci. U.S.A.,* **100,** 2231–2236.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.,* **150** (Suppl. 1)**,** S1–S168.

Thyroid hormone

Overview: Thyroid hormone receptors (TRs, provisional nomenclature) are nuclear hormone receptors of the NR1A family, with diverse roles regulating macronutrient metabolism, cognition and cardiovascular homeostasis. TRs are activated by thyroxine (T4) and thyroid hormone (T3). Once activated by a ligand, the receptor acts as a transcription factor either as a monomer, homodimer or heterodimer with members of the retinoid X receptor family.

Nomenclature	**TRα**	**TRβ**
Other names	NR1A1, THRA, erbAα, erbA1, EAR7	NR1A2, THRB, erbAβ, erbA2
Ensemble ID	ENSG00000126351	ENSG00000151090
Rank order of potency	T3 > T4	T3 > T4
Selective agonists	—	GC1 (Chiellini *et al*., 1998)

One splice variant, TRα_2, lacks a functional DNA-binding domain and appears to act as a transcription suppressor. Although radioligand binding assays have been described for these receptors, the radioligands are not commercially available.

Abbreviations: **GC1**, (3,5-dimethyl-4-[4-hydroxy-3-isopropylbenzyl]phenyloxy)acetate

Further Reading:

BAXTER, J.D., WEBB, P., GROVER, G. & SCANLAN, T.S. (2004). Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. *Trends Endocrinol. Metab.,* **15,** 154–157.

CHENG, S.Y. (2005). Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. *Trends Endocrinol. Metab.,* **16,** 176–182.

GROVER, G.J. & MALM, J. (2005). Selective thyroid hormone agonists: a strategy for treating metabolic syndrome. *Drug Discov. Today: Ther. Strat.,* **2,** 137–142.

KOIBUCHI, N. & IWASAKI, T. (2006). Regulation of brain development by thyroid hormone and its modulation by environmental chemicals. *Endocr. J.*, **53**, 295–303.

SHI, Y.B., RITCHIE, J.W. & TAYLOR, P.M. (2002). Complex regulation of thyroid hormone action: multiple opportunities for pharmacological intervention. *Pharmacol. Ther.,* **94,** 235–251.

VASUDEVAN, N., OGAWA, S. & PFAFF, D. (2002). Estrogen and thyroid hormone receptor interactions: physiological flexibility by molecular specificity. *Physiol. Rev.,* **82,** 923–944.

YEN, P.M. (2003). Molecular basis of resistance to thyroid hormone. *Trends Endocrinol. Metab.,* **14,** 327–333.

YEN, P.M., ANDO, S., FENG, X., LIU, Y., MARUVADA, P. & XIA, X. (2006). Thyroid hormone action at the cellular, genomic and target gene levels. *Mol. Cell. Endocrinol.*, **246,** 121–127.

References:

CHIELLINI, G. *et al*. (1998). *Chem. Biol.,* **5,** 299–306.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.,* **150** (Suppl. 1)**,** S1–S168.